RPL17 and hepatocellular carcinoma: In our study, HCC patients in the low risk score group had a higher anti-PD 1 IPS, anti-CTLA4 IPS and anti-PD 1 and CTLA4 IPS than those in the high risk score group (Fig. 5A, all p < 0.05).